Stockscreener 앱 받기
57.59
2.51%
-1.48
시장 영업 전:
61.00
3.41
+5.92%
Livanova Plc 주식(LIVN)의 최신 뉴스
Earnings Flash (LIVN) LivaNova PLC Reports Q1 Revenue $362.3M, vs. FactSet Est of $346.1M - marketscreener.com
Earnings Flash (LIVN) LivaNova PLC Posts Q1 Adjusted EPS $0.98 per Share, vs. FactSet Est of $0.90 - marketscreener.com
LivaNova beats estimates but shares fall 2% on guidance concerns By Investing.com - Investing.com Nigeria
LivaNova: Q1 Earnings Snapshot - KTVB
LivaNova plc (LIVN) Tops Q1 EPS by 8c, Beats on Revenue; Offers FY26 EPS Guidance - StreetInsider
LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance - Business Wire
MSN Money - MSN
LivaNova earnings ahead as reimbursement tailwinds build By Investing.com - Investing.com Nigeria
Avoiding Lag: Real-Time Signals in (LIVN) Movement - Stock Traders Daily
LivaNova (LIVN) Projected to Post Earnings on Wednesday - MarketBeat
LivaNova PLC (LIVN) Shares Fall 3.3% -- GF Value Says Still Over - GuruFocus
LivaNova gains FDA premarket approval for Aura6000 for sleep apnea - MSN
Will OSPREY Trial Data on aura6000 Sleep Apnea Device Change LivaNova's (LIVN) Narrative - simplywall.st
Peregrine Capital Management LLC Invests $3.83 Million in LivaNova PLC $LIVN - MarketBeat
LivaNova (NASDAQ:LIVN) Shares Cross Below 50 Day Moving AverageHere's Why - MarketBeat
Global Perfusion Systems Market to Register Incremental Growth at a CAGR of ~5% by 2034 | DelveInsight - GlobeNewswire Inc.
Neurostimulation Devices Market to Reach USD 17.82 Billion - openPR.com
Discipline and Rules-Based Execution in LIVN Response - Stock Traders Daily
Annals of Internal Medicine Publishes 12-Month Results from LivaNova’s OSPREY Clinical Study for Obstructive Sleep Apnea - BioSpace
LivaNova PLC stock (US5356991077): Why does its medtech innovation edge matter more now? - AD HOC NEWS
Tissue Heart Valves Market Key Companies AnalysisEdwards - openPR.com
LivaNova PLC (NASDAQ:LIVN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Best Time to Sell LivaNova PLC (LIVN) Stock (Institutional Selling) 2026-04-16Insider Selling - Xã Châu Thành
In-Line Blood Monitoring Devices Market to Reach USD 0.42 - openPR.com
33,332 Shares in LivaNova PLC $LIVN Acquired by Tudor Investment Corp ET AL - MarketBeat
Behavioral Patterns of LIVN and Institutional Flows - Stock Traders Daily
Nasdaq Moves: Whats the fair value of LivaNova PLC stockMarket Performance Recap & Weekly Momentum Stock Picks - baoquankhu1.vn
Aberdeen Group plc Lowers Stock Holdings in LivaNova PLC $LIVN - MarketBeat
Market Catalysts: Is LivaNova PLC stock a falling knife or bargain buy2026 Trends & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
LivaNova PLC (LIVN) Stock Forecasts - Yahoo Finance
Allspring Global Investments Holdings LLC Reduces Stake in LivaNova PLC $LIVN - MarketBeat
Exchange Traded Concepts LLC Buys New Shares in LivaNova PLC $LIVN - MarketBeat
LivaNova PLC (LIVN) Stock forecasts - Yahoo Finance UK
LivaNova to present at JP Morgan Healthcare Conference in January - MSN
(LIVN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Aug Macro: Does LivaNova PLC stock benefit from AI growth2026 Earnings & Daily Volume Surge Signals - baoquankhu1.vn
Tudor Investment Corp ET AL Acquires Shares of 33,332 LivaNova PLC - National Today
Tudor Investment Corp ET AL Acquires Shares of 33,332 LivaNova PLC $LIVN - marketbeat.com
How FDA Approval of Aura6000 Sleep Apnea Therapy Will Impact LivaNova (LIVN) Investors - Sahm
Should FDA Approval of aura6000 Sleep Apnea Therapy Require Action From LivaNova (LIVN) Investors? - Yahoo Finance
LivaNova (LIVN) Announces FDA Approval of aura6000 System for Obstructive Sleep Apnea - Insider Monkey
LivaNova Broadens OSA Treatment Options With FDA Clearance for aura6000 System - Bitget
LivaNova Expands OSA Care With FDA-Approved aura6000 System - Yahoo Finance
LivaNova to Announce First-Quarter 2026 Results - Business Wire
LivaNova PLC stock faces analyst scrutiny amid mixed ratings and modest growth outlook in medical de - AD HOC NEWS
LivaNova PLC (LIVN) Stock Analysis: Evaluating a 26% Upside Potential in the Medical Device Sector - DirectorsTalk Interviews
LivaNova PLC (NASDAQ:LIVN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
FDA Approves Hypoglossal Nerve Stimulation Device for OSA - Medical Dialogues
0.41%
0.93%
자본화:
|
볼륨(24시간):